Evaluation of Immunogenicity of Mycobacterium tuberculosis ag85ab DNA Vaccine Delivered by Pulmonary Administration DOI Creative Commons
Haimei Zhao, Zhen Zhang, Yong Xue

и другие.

Vaccines, Год журнала: 2025, Номер 13(5), С. 442 - 442

Опубликована: Апрель 23, 2025

Background: Tuberculosis (TB) is a respiratory infectious disease, and the current TB vaccine has low local lung protection. We aim to optimize immune pathways improve immunogenicity of vaccines. Methods: In study, 50 BALB/c mice were randomly divided into following: (1) phosphate buffered saline (PBS)+intramuscular injection combined with electroporation (EP) group (100 μL), (2) pVAX1+EP (50 μg/100 (3) ag85ab+EP (4) pVAX1+pulmonary delivery (PD) μg/50 (5) ag85ab+PD μL). Immunization was given once every 2 weeks for total three times. The number IFN-γ-secreting spleen lymphocytes determined by enzyme-linked immunospot assay (ELISPOT). levels Th1, Th2, Th17 cytokines in culture supernatants detected Luminex method. proportion FoxP3 regulatory T cells splenocytes flow cytometry. IgG-, IgG1-, IgG2a-specific antibodies plasma IgA antibody bronchoalveolar lavage fluid (BALF) immunosorbent (ELISA). Results: PD EP routes Mycobacterium tuberculosis (M. tb) ag85ab DNA can effectively induce responses lymphocytes, dominant Th1 cell responses. route earlier, greater numbers stronger pulmonary effector cells, higher specific BALF. High IgG, IgG1, IgG2α immunized route. Conclusions: vaccines more stimulate body produce strong cellular mucosal immunity than route, especially lungs, which provide early protection lungs. It significantly vaccine, suggesting feasible effective approach immunization.

Язык: Английский

Bioinformatics analysis, immunogenicity, and therapeutic efficacy evaluation of a novel multi-stage, multi-epitope DNA vaccine for tuberculosis DOI Creative Commons
Jinlei Guo, Zaixing Jia, Yourong Yang

и другие.

International Immunopharmacology, Год журнала: 2025, Номер 152, С. 114415 - 114415

Опубликована: Март 13, 2025

Язык: Английский

Процитировано

0
Evaluation of Immunogenicity of Mycobacterium tuberculosis ag85ab DNA Vaccine Delivered by Pulmonary Administration DOI Creative Commons
Haimei Zhao, Zhen Zhang, Yong Xue

и другие.

Vaccines, Год журнала: 2025, Номер 13(5), С. 442 - 442

Опубликована: Апрель 23, 2025

Background: Tuberculosis (TB) is a respiratory infectious disease, and the current TB vaccine has low local lung protection. We aim to optimize immune pathways improve immunogenicity of vaccines. Methods: In study, 50 BALB/c mice were randomly divided into following: (1) phosphate buffered saline (PBS)+intramuscular injection combined with electroporation (EP) group (100 μL), (2) pVAX1+EP (50 μg/100 (3) ag85ab+EP (4) pVAX1+pulmonary delivery (PD) μg/50 (5) ag85ab+PD μL). Immunization was given once every 2 weeks for total three times. The number IFN-γ-secreting spleen lymphocytes determined by enzyme-linked immunospot assay (ELISPOT). levels Th1, Th2, Th17 cytokines in culture supernatants detected Luminex method. proportion FoxP3 regulatory T cells splenocytes flow cytometry. IgG-, IgG1-, IgG2a-specific antibodies plasma IgA antibody bronchoalveolar lavage fluid (BALF) immunosorbent (ELISA). Results: PD EP routes Mycobacterium tuberculosis (M. tb) ag85ab DNA can effectively induce responses lymphocytes, dominant Th1 cell responses. route earlier, greater numbers stronger pulmonary effector cells, higher specific BALF. High IgG, IgG1, IgG2α immunized route. Conclusions: vaccines more stimulate body produce strong cellular mucosal immunity than route, especially lungs, which provide early protection lungs. It significantly vaccine, suggesting feasible effective approach immunization.

Язык: Английский

Процитировано

0